MYP_169942
Griselimycin
Antimicrobial
Standard
10 amino acids
C48H82N10O12
Standard
VPSLPLVPLG
991.22 Da
5.50
-0.27
-0.48
-0.0266
1.38
0.03
0.60
86.04
175.00
0.0000
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Amino Acid Composition
319.08
-0.65
9.0
12.0
25.0
70.0
3.0
9.0
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
RECORD: Rec_0343571
VERIFIED: YES
Provenance & Taxonomy
Synthetic construct [Synthetic]
Bacteriocin
32630
Structure & Mods
head-to-tail cyclic peptide [Cyclic]
canonical L-amino-acid peptide [L]
Esterification
Griselimycin was initially found in the 1960s ( Terlain B, Thomas JP. Bull Soc Chim Fr. 1971 Jun;6:2349-56). Chemical modification: SAR: The full synthetic derivatives (MGM and CGM) are better suited as a possible candidate to treat susceptible and resistant M. tuberculosis (anti-TB). MGM is a derivative with Pro8 methylated, while CGM is a derivative with Pro8 cyclohexylated. MOA: It works by inhibiting the DNA polymerase sliding clamp DnaN (4 crystal structures of the complex have been deposited into the PDB). Structure: You can rotate, zoom, and view one of the 3D structures here in the PDB. Animal model:mouse: CGM showed in vivo efficacy in a mouse model of TB. Updated 7/2021
Bio-Activity Profile
Antimicrobial